Cost-effectiveness of ultra-low-dose quadruple combination therapy for high blood pressure

Conclusion(s)
Quadpill in comparison with monotherapy is comparably cost-effective for short-term BP lowering. In the long-term, quadpill therapy is likely to be cost-effective.

Trial registration number
ANZCTRN12616001144404.

Source: Heart - October 26, 2023 Category: Cardiology Authors: Atkins, E. R., Chye, A., Lung, T., Nolde, J. M., Billot, L., Burke, M., Chalmers, J., Figtree, G. A., Hay, P., Hillis, G. S., Jansen, S., Marschner, S., Neal, B., Nelson, M. R., Reid, C. M., Usherwood, T., Schlaich, M., Chow, C. K., Rodgers, A. Tags: Healthcare delivery, economics and global health Source Type: research